Idorsia Ltd (LON: 0RQE)
London
· Delayed Price · Currency is GBP · Price in CHF 0.705
-0.015 (-2.02%)
At close: Jan 31, 2025
Idorsia Revenue
Idorsia had revenue of 26.20M CHF in the quarter ending September 30, 2024, a decrease of -67.21%. This brings the company's revenue in the last twelve months to 74.12M, down -59.87% year-over-year. In the year 2023, Idorsia had annual revenue of 152.39M with 56.93% growth.
Revenue (ttm)
74.12M CHF
Revenue Growth
-59.87%
P/S Ratio
n/a
Revenue / Employee
114.03K CHF
Employees
650
Market Cap
117.39M GBP
Revenue Chart
* This company reports financials in CHF.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| AstraZeneca | 38.20B |
| GSK plc | 31.31B |
| Haleon | 11.24B |
| Smith & Nephew | 4.46B |
| Hikma Pharmaceuticals | 2.39B |
| ConvaTec Group | 1.74B |
| HUTCHMED (China) | 483.31M |
| Oxford Nanopore Technologies | 167.75M |